Search Results
Phase II ADAPT Trial in Patients With HER2+ and HR+ Early Breast Cancer
Dr. Yee on Phase II ADAPT Trial Results for HER2+/HR+ Breast Cancer
Outcomes from ADAPT-HR-/HER2+ evaluating dual HER2 blockade
Prognostic score in early HR+/HER2- breast cancer: RS, factors, mutations, histology
HER2+ Early-Stage Breast Cancer: Peri-Operative Therapy
New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Mahtani & Dr. Schwartzberg
New horizons in high-risk HR+ HER2- EBC: Risk stratification for early identification
The impact of biomarkers on pCR and survival in WSG ADAPT TP
APHINITY Trial for HER2+ Breast Cancer
Raising the Bar in HR+/HER2- Early Breast Cancer: CDK4 and 6 Inhibitors
Trial investigates multiparametric prognostic score in early HR+/HER2- breast cancer
Neoadjuvant T-DM1 in HER2+ Early Breast Cancer
